TSE:CPH

Cipher Pharmaceuticals - CPH Stock Forecast, Price & News

C$3.35

+0.01 (+0.30%)

(As of 03/23/2023 12:00 AM ET)

Add

Compare

Today's Range: C$3.30
▼
C$3.46
50-Day Range: C$3.34
▼
C$3.87
52-Week Range: C$2.00
▼
C$4.07

Volume: 39,754 shs
Average Volume: 13,343 shs
Market Capitalization: C$84.02 million

P/E Ratio: 7.28
Dividend Yield: N/A
Price Target: N/A

About Cipher Pharmaceuticals (TSE:CPH) Stock

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

Receive CPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPH Stock News Headlines

March 19, 2023 | seekingalpha.com

Cipher Pharmaceuticals Non-GAAP EPS of -$0.12

March 16, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

March 24, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

March 1, 2023 | finance.yahoo.com

Cipher Pharmaceuticals Announces Closing of New US$35 Million Credit Facility

December 21, 2022 | seekingalpha.com

CPH:CA Cipher Pharmaceuticals Inc.

December 4, 2022 | finance.yahoo.com

Cipher Pharmaceuticals Inc.'s (TSE:CPH) Stock Is Going Strong: Have Financials A Role To Play?

November 13, 2022 | finance.yahoo.com

Cipher Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

September 14, 2022 | baystreet.ca

Signa, Boardwalktech, Cipher at 52-Week Highs

March 24, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

August 5, 2022 | finance.yahoo.com

Cipher Pharmaceuticals Schedules Q2 2022 Earnings Release and Conference Call

June 22, 2022 | finance.yahoo.com

Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders and Thanks Director Dr. John Mull

March 17, 2022 | finance.yahoo.com

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

November 11, 2021 | finance.yahoo.com

Cipher Announces Third Quarter and Year-to-Date 2021 Financial Results

November 3, 2021 | finance.yahoo.com

Cipher Pharmaceuticals Schedules Q3 2021 Earnings Release and Conference Call

October 19, 2021 | finance.yahoo.com

Investing in Cipher Pharmaceuticals (TSE:CPH) a year ago would have delivered you a 155% gain

September 8, 2021 | finance.yahoo.com

Cipher Pharmaceuticals Announces Renewal of Normal Course Issuer Bid

August 12, 2021 | finance.yahoo.com

Cipher Reports 30% Revenue Growth and 40% Adjusted EBITDA Growth in Second Quarter of 2021, Driven by Strength in Epuris and Absorica

August 9, 2021 | ca.finance.yahoo.com

Stocks in play: Cipher Pharmaceuticals Inc.

June 23, 2021 | finance.yahoo.com

Cipher Pharmaceuticals Reports Voting Results From Annual Meeting of Shareholders

May 14, 2021 | markets.businessinsider.com

Cipher Pharmaceuticals Reports First Quarter 2021 Financial Results

May 5, 2021 | finance.yahoo.com

Cipher Pharmaceuticals Schedules Q1 2021 Earnings Release and Conference Call

April 2, 2021 | finance.yahoo.com

Cipher Pharmaceuticals Inc.'s (TSE:CPH) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

March 18, 2021 | markets.businessinsider.com

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

January 16, 2021 | benzinga.com

Cipher Pharmaceuticals Receives Arbitration Award on Trulance®

January 7, 2021 | wsj.com

Cipher Pharmaceuticals Inc.

December 3, 2020 | marketwatch.com

Outlook on the Acne Drugs Global Market to 2025 - Impact Analysis of COVID-19

November 10, 2020 | marketwatch.com

Actinic Keratosis Treatment Market Forecast Revised in a New FMI Report as COVID-19 Projected to Hold a Massive Impact on Sales in 2028

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPH Company Calendar

Today: 3/24/2023
Next Earnings (Estimated): 5/11/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:CPH
Previous Symbol: TSE:DND
CUSIP: N/A
CIK: N/A
Web: www.cipherpharma.com
Phone: +1-905-6025840
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): C$0.46
Trailing P/E Ratio: 7.28
Forward P/E Ratio: 8.93
P/E Growth: N/A
Net Income: C$26.64 million
Net Margins: 128.83%
Pretax Margin: N/A
Return on Equity: 51.73%
Return on Assets: 11.01%

Debt

Debt-to-Equity Ratio: 0.67
Current Ratio: 4.07
Quick Ratio: 2.67

Sales & Book Value

Annual Sales: C$20.68 million
Price / Sales: 4.06
Cash Flow: C$0.95 per share
Price / Cash Flow: 3.53
Book Value: C$2.56 per share
Price / Book: 1.31

Miscellaneous

Outstanding Shares: 25,080,000
Free Float: N/A
Market Cap: C$84.02 million
Optionable: Not Optionable
Beta: 1.02

Key Executives

Mr. Craig J. Mull
Interim CEO & Chairman

Dr. Diane Gajewczyk
VP of Scientific & Medical Affairs

Mr. Bryan Jacobs
Chief Financial Officer

Mr. Emilio Presti
Director of Sales, Marketing & Hospital Bus.

Chuoru Li
Corp. Controller

David Miller
Director of Fin.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

CPH Stock - Frequently Asked Questions

Should I buy or sell Cipher Pharmaceuticals stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPH shares.
View CPH analyst ratings or view top-rated stocks.
How have CPH shares performed in 2023?: Cipher Pharmaceuticals' stock was trading at C$3.84 at the beginning of 2023. Since then, CPH shares have decreased by 12.8% and is now trading at C$3.35.
View the best growth stocks for 2023 here.
When is Cipher Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our CPH earnings forecast.
What other stocks do shareholders of Cipher Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Bellatrix Exploration (BXE), Aurora Cannabis (ACB), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Ampio Pharmaceuticals (AMPE), Catalyst Biosciences (CBIO), Crescent Point Energy (CPG) and Enbridge (ENB).

What is Cipher Pharmaceuticals' stock symbol?: Cipher Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CPH."
How do I buy shares of Cipher Pharmaceuticals?: Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Cipher Pharmaceuticals' stock price today?: One share of CPH stock can currently be purchased for approximately C$3.35.
How much money does Cipher Pharmaceuticals make?: Cipher Pharmaceuticals (TSE:CPH) has a market capitalization of C$84.02 million and generates C$20.68 million in revenue each year. The company earns C$26.64 million in net income (profit) each year or C$0.46 on an earnings per share basis.
How can I contact Cipher Pharmaceuticals?: Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The official website for the company is www.cipherpharma.com. The company can be reached via phone at +1-905-6025840.

This page (TSE:CPH) was last updated on 3/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial